Skip to main content
. 2019 Jun 11;10:647. doi: 10.3389/fphar.2019.00647

Figure 1.

Figure 1

Myricetin treatment attenuated streptozotocin (STZ)-induced diabetic nephropathy. (A) Blood glucose (n ≥ 12); (B) representative images (400×) of hematoxylin and eosin (H&E) staining of kidneys (n = 6); (C) calculated glomerular area; (D) body weight (BW) (n ≥ 12); (E) kidney weight (KW)/BW ratio (n ≥ 12); (F) KW/tibia length (TB) ratio (n ≥ 12); (G) urinary albumin-to-creatinine ratio (UACR) (n ≥ 12). Data are presented as the mean ± SD. *p < 0.05 vs. the Con group, # p < 0.05 vs. the STZ group.